Arthneeti

Anthem Biosciences Q1 FY27 Share Price & Earnings Call Analysis

₹828.80-0.16% today
Market cap
₹46,678 Cr
P/E
78.66
ROE
22.28%
PEG
3.79
Price to sales
23.31
Debt to equity
0.02
52W high / low
₹958 / ₹592
Sales growth (5Y)
14.00%
EBITDA margin
39.60%
Net profit margin
28.59%
Promoter holding
71.39%
Sales (last year)
₹2,002 Cr

Guidance scorecard · Q1 FY27 call

What Anthem Biosciences Ltd's management guided
and where it ranks in Pharmaceuticals & Biotechnology

#62of 84 in
Pharmaceuticals & Biotechnology
Revenue10–20%MarginsFlatCapexPlannedFundraisingWhat management saidOrder bookWhat management said

RevenueQ1 FY27 call

10–20%
  • Anthem expects overall growth for FY27 to remain intact and consistent with its historical double-digit performance.
  • Q1 was a soft quarter with about a 25% YoY decline, but Q2, Q3, and Q4 are expected to see recovery and growth.
  • The business is characterized by quarterly fluctuations (lumpiness) due to customer delivery scheduling.
  • A strong order book with about 60% visibility for the full year provides confidence in achieving growth targets.
  • Growth in specialty ingredients, affected by supply chain pressures, is expected to recover strongly by year-end.
  • New customers, including a recently added Big Pharma client, and increased volumes from existing clients will contribute to growth.

2 more points from Anthem Biosciences Ltd's call on revenue

Create a free account to keep reading this call

Full Q1 FY27 analysis

MarginsQ1 FY27 call

Flat

See what Anthem Biosciences Ltd said on margins — free account, 30 seconds.

Full Q1 FY27 analysis

CapexQ1 FY27 call

Planned

Ask what Anthem Biosciences Ltd said on capex →

Full Q1 FY27 analysis

FundraisingQ1 FY27 call

See what Anthem Biosciences Ltd said on fundraising — free account, 30 seconds.

Full Q1 FY27 analysis

Order bookQ1 FY27 call

  • At the start of FY27, Anthem had about 60% of its order book for the full year's delivery already secured.
  • After Q1, despite a muted quarter, the order book was replenished and still stands at approximately 60%.
  • This 60% visibility covers the entire business, including CRDMO, specialty ingredients, and R&D segments.
  • The remaining 40% of the order book typically comes from onboarding new customers or increased volumes from existing clients.
  • Orders are a mix of confirmed and anticipated purchase orders, with rolling forecasts updated every 3 to 6 months.

2 more points from Anthem Biosciences Ltd's call on the order book

Create a free account to keep reading this call

Full Q1 FY27 analysis
Full Pharmaceuticals & Biotechnology ranking

Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.

Potential multibaggers · Q2 FY27

Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. Strong growth
    3
See all potential multibaggersWhere does Anthem Biosciences Ltd rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Pharmaceuticals & Biotechnology companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹556 Cr22.1
240%+Up 0–2%₹215 Cr22.2
340%+Flat₹16,144 Cr—
440%+Flat₹6,072 Cr48.0
540%+Flat₹40 Cr—
620–40%Up 2%+₹50,220 Cr43.8

Sign up free to see every company in the sector ranking and track Anthem Biosciences Ltd.

Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology ranking

Financials of Anthem Biosciences Ltd

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Financials of Anthem Biosciences Ltd

Quarterly Results

Quarter-by-quarter operating performance

Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales +339525498483540550423611
Expenses +218330338288349332266344
Operating Profit121195160195191218157267
OPM %36%37%32%40%35%40%37%44%
Other Income +192824142348852
Interest44312302
Depreciation1920203026343540
Profit before tax118200161178186230130278
Tax %30%19%23%54%27%24%29%32%
Net Profit +821621248313617393190
EPS in Rs1.472.902.221.482.423.091.653.38

Financials of Anthem Biosciences Ltd

Profit & Loss

Annual income statement trend

Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales +6331,1031,2311,0571,4191,8452,124
Expenses +4516956666269141,1731,291
Operating Profit182408565431506672834
OPM %29%37%46%41%36%36%39%
Other Income +2137491396385131
Interest201710910117
Depreciation626258648289134
Profit before tax121366546497477657824
Tax %23%26%26%23%23%31%28%
Net Profit +93271406385367451592
EPS in Rs110.62319.74462.096.756.578.0710.54
Dividend Payout %0%0%0%0%0%0%0%

Financials of Anthem Biosciences Ltd

Balance Sheet

Capital structure and asset base

Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital889114112112112
Reserves4136931,3461,6271,8132,2982,930
Borrowings +1591003512623911353
Other Liabilities +207232228148235284334
Total Liabilities7871,0341,6192,0142,3982,8083,429
Fixed Assets +306361329449483705783
CWIP5019154164345297264
Investments992092734994724331,007
Other Assets +3334458639021,0991,3731,374
Total Assets7871,0341,6192,0142,3982,8083,429

Financials of Anthem Biosciences Ltd

Cash Flows

Operating, investing and financing cash movement

Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +166278333306140418844
Cash from Investing Activity +-109-196-205-376-221-152-702
Cash from Financing Activity +-48-6318164-77-134-40
Net Cash Flow918308-6-158133103
Free Cash Flow119159307112-156154637
CFO/OP116%85%81%98%51%86%126%

Financials of Anthem Biosciences Ltd

Ratios

Working capital efficiency and return ratios

Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days6184979512689101
Inventory Days186295213912916756
Days Payable87505077615434
Cash Conversion Cycle1606399156193202124
Working Capital Days202775112128134207
ROCE %55%51%28%24%28%30%

Guidance history

How Anthem Biosciences Ltd's guidance has moved, call by call

CallRevenueMarginsCapexFundraisingOrder book
Q1 FY27 call →10–20%FlatPlanned——
Q4 FY26 call →20–40%FlatPlanned—Rising
Q3 FY26 call →10–20%FlatPlanned——
Q2 FY26 call →20–40%FlatPlanned—Rising

What management guided on each call, newest first. Not investment advice, and not a forecast of returns.

70out of 100

Momentum score · price trend

70 out of 100 — Strengthening

Over the past year its share price has done better than most of the stocks we track.

PeriodShare price changeBetter than … of 1,910 stocks
Last 12 months+15.5%72%
Last 6 months+9.0%67%
Last 3 months+2.4%71%
How we calculate it

“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).

The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Anthem Biosciences Ltd: 0.4 × 72 + 0.4 × 67 + 0.2 × 71 = 70.

Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.

Full methodology →

This describes only how the share price has moved up to 30 Oct 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.

Continue your research

What Anthem Biosciences Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Accretion Pharmaceuticals Ltd (Q2 FY27)

    25.85% increase) . Key results statement takeaways from Accretion Pharmaceuticals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Sigachi Industries Ltd (Q2 FY27)

    Year-on-Year (YoY) Revenue Growth: 18.09% (Q2 FY27 vs Q2 FY26) . Key investor presentation takeaways from Sigachi Industries Ltd's Q2 FY27 investor presentation

  • Advanced Enzyme Technologies Ltd (Q2 FY27)

    Q2 FY27 revenue from operations: ₹2,145 million, up 16% YoY from ₹1,845 million in Q2 FY26 (Page 13, 5). Key investor presentation takeaways from Advanced Enzym

  • IOL Chemicals (Q2 FY27)

    Q2 FY27 revenue from operations: ₹795.0 Cr, a 40.1% year-on-year (YoY) increase from ₹567.5 Cr in Q2 FY26 (Page 7). Key investor presentation takeaways from IOL

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd